Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide monotherapy in advanced multiple myeloma
NCT00622336Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2003
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of lenalidomide in multiple myeloma (MM), sponsored by Celgene Corporation. Started Apr 2003; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00622336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00622336.